Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Recursion reported initial monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors.

First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesized

Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close

OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new “gold standard” outperforming CellProfiler

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment of symptomatic CCM in subsequent studies.

Rebecca Chavez-Houck and Chris Gibson bring unique perspectives to board that oversees the nonprofit news outlet, they said.

Published open-access today in Nature Genetics, “High-resolution genome-wide mapping of chromosome-arm-scale truncations induced by CRISPR–Cas9 editing” identifies novel evidence of a proximity bias in CRISPR-Cas9 gene knockouts and a debiasing (correcting) algorithm.

BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024.